Selected clinical programmes and approved medicines
Phase 2
Phase 3
Filed
Approved
Eli Lilly
12 selected programmes · as listed 5 Aug 2026
Obesity & cardiometabolic
Retatrutide
Eloralintide
Lepodisiran
Insulin efsitora alfa
Mounjaro / Zepbound
Foundayo
Cancer
Olomorasib
Jaypirca
Immunology
Zotemtegrast
Ebglyss
Neuroscience
Brenipatide
Kisunla
Novo Nordisk
12 selected programmes · as listed 12 Sep 2026
Obesity & cardiometabolic
Zenagamtide (oral)
Monlunabant
UBT251
Zenagamtide (injection)
Cagrilintide
Efruxifermin
Ziltivekimab
Coramitug
CagriSema
Ozempic / Wegovy
Rare blood disorders
Etavopivat
Denecimig